Frontiers in Cardiovascular Medicine最新文献

{"title":"Scanner-generated native T1 mapping: a novel approach for assessing myocardial fibrosis in coronary heart disease.","authors":"Li Kong, Xiaohong Tian, Bing Ji, Jian Wang, Hongqin Liang, Xiaojuan Ji","doi":"10.3389/fcvm.2025.1553919","DOIUrl":"https://doi.org/10.3389/fcvm.2025.1553919","url":null,"abstract":"<p><strong>Background: </strong>To investigate the feasibility of using native longitudinal relaxation time (T1) mapping values, derived from the Picture Archiving and Communication System (PACS), for assessing diffuse myocardial fibrosis in patients with coronary heart disease (CHD).</p><p><strong>Materials and methods: </strong>Patients with CHD group were retrospectively enrolled as the experimental group, while age- and sex-matched healthy individuals were included as the control group. Based on the results of late gadolinium enhancement (LGE) sequence from cardiac magnetic resonance (CMR) imaging, the CHD group was further stratified into two subgroups: the LGE positive group (LGE+) and the LGE negative group (LGE-). The correlation between native T1 values and extracellular volume (ECV) values were assessed using the Pearson correlation coefficient.</p><p><strong>Results: </strong>A total of 60 patients with coronary heart disease (age 54.03 ± 9.86 years) were included in the analysis, of whom 30 had late gadolinium enhancement (LGE+) and 30 did not (LGE-). The control group consisted of 42 healthy subjects (age 52.14 ± 7.41 years). Compared with the control group, both native T1 and extracellular volume (ECV) values were significantly increased in the CHD group (<i>P</i> < 0.05). The native T1 value was positively correlated with the ECV value (<i>r</i> = 0.711, <i>P</i> < 0.01). In the LGE+ subgroup, native T1 and ECV values were significantly higher than those in the control group (<i>P</i> < 0.001). The area under the receiver operating characteristic curve (AUC) for native T1 was 0.763. The optimal diagnostic threshold for native T1, as measured by the Picture Archiving and Communication System (PACS), was 1,275.50 ms, with a sensitivity of 93.3% and a specificity of 63.3%.</p><p><strong>Conclusions: </strong>The diagnostic performance of scanner-generated native T1 Mapping demonstrates robust accuracy and holds potential as a non-invasive tool for evaluating diffuse myocardial fibrosis in patients with CHD.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1553919"},"PeriodicalIF":2.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12078203/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Coronary angiography-derived index of microcirculatory resistance associated with contrast-induced acute kidney injury in patients with STEMI.","authors":"Sifang Zhong, Jinyang Lu, Kaiyue Gong, Yixuan Wu, Zishuang Dong, Yuan Lu","doi":"10.3389/fcvm.2025.1541208","DOIUrl":"https://doi.org/10.3389/fcvm.2025.1541208","url":null,"abstract":"<p><strong>Background: </strong>More than half of ST-segment elevation myocardial infarction (STEMI) patients have coronary microcirculatory dysfunction (CMD) after percutaneous coronary intervention (PCI). This study aimed to explore the role of CMD in the occurrence of contrast-induced acute kidney injury (CI-AKI) in patients with STEMI.</p><p><strong>Methods: </strong>This was a single-centre retrospective clinical observational study. Coronary angiography-derived index of microcirculatory resistance (caIMR) was measured and used to assess CMD. Regression analysis was used to identify risk factors for CI-AKI. Restricted cubic splines (RCS) was employed to examine the dose-response relationship between caIMR and CI-AKI. The predictive accuracy of the models was assessed with net reclassification index (NRI), and integrated discrimination improvement (IDI).</p><p><strong>Results: </strong>This study included 745 patients, the incidence of CI-AKI was 10.6% (79/745). Multivariate logistic regression identified caIMR (OR = 1.072, 95% CI: 1.051-1.094) as an independent predictor of CI-AKI. RCS analysis indicated a linear dose-response relationship between caIMR and CI-AKI. Receiver operating characteristic (ROC) analysis demonstrated that the areas under the curve for caIMR was 0.725, the optimal cutoff value was 25.95 U. Integration of caIMR could significantly improve the risk model for CI-AKI in STEMI patients (NRI = 0.721, IDI = 0.102, <i>P</i> < 0.001).</p><p><strong>Conclusions: </strong>Elevated caIMR is an independent risk factor for the development of CI-AKI after PCI in STEMI patients. Integrating caIMR significantly improves the risk model for CI-AKI.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1541208"},"PeriodicalIF":2.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12078307/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Off-pump total arterial bypass grafting for the elderly does not improve life expectancy.","authors":"Nuttapon Arayawudhikul, Ryohei Ushioda, Hideki Isa, Dit Yoongtong, Boonsap Sakboon, Jaroen Cheewinmethasiri, Thanin Lokeskrawee, Jayanton Patumanond, Suppachai Lawanaskol, Hiroyuki Kamiya","doi":"10.3389/fcvm.2025.1598770","DOIUrl":"https://doi.org/10.3389/fcvm.2025.1598770","url":null,"abstract":"<p><strong>Objectives: </strong>To assess whether total arterial revascularization (TAR) offers survival and freedom from major adverse cardiac or cerebrovascular events (MACCE) benefit in elderly patients with multivessel coronary artery disease undergoing off-pump coronary artery bypass grafting (OPCAB), as compared to using a single internal thoracic artery (ITA) with additional saphenous vein graft (SVG).</p><p><strong>Methods: </strong>We retrospectively analyzed 598 patients aged >70 years who underwent coronary revascularization from August 2017-July 2023. After excluding high-risk patients and those with SVG plus more than two arterial grafts, 428 patients remained (101, TAR group; 327, single ITA + SVG group). A propensity score was used to create the TAR and single ITA + SVG groups with 1:1 ratio (100 patients in each group). Moreover, matching was performed based on eight covariates with preoperative clinical characteristics.</p><p><strong>Results: </strong>The unmatched cohort had 70 (69.3%) and 178 (54.4%) men in the TAR and ITA + SVG groups, respectively (mean age, 74.1 ± 3.5 and 75.2 ± 4.2 years, respectively). After matching, both groups had similar demographics. The survival (<i>p</i> = 0.410) and MACCE-free rates (<i>p</i> = 0.494) over 5 years were not significantly different between the two groups. Univariable analysis showed that TAR [hazard ratio (HR) = 0.74, 95% confidence interval (CI) = 0.44-1.22, <i>p</i> = 0.233] and complete revascularization (HR = 0.61, 95%CI = 0.34-1.09, <i>p</i> = 0.094) were not significant risk factors for long-term mortality.</p><p><strong>Conclusion: </strong>Elderly patients who underwent OPCAB with total arterial grafting did not show survival or free-MACCE benefits for over 5 years.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1598770"},"PeriodicalIF":2.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12078303/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of SGLT2 inhibitors in acute heart failure: a systematic review and meta-analysis of randomized controlled trials.","authors":"Ali Ibrahim Rahil, Tirth Bhavsar, Romman Fatima, Aparajitha Rajkumar, Joy Kumar, Hanif Al Majidan, Namrata Gajjala, Wodwentzky Lefranc, Fnu Deeksha, Harshitha Lingegowda, Muhammad Ehsan, Wajeeh Ur Rehman, Hasan Ahmad, Raheel Ahmed","doi":"10.3389/fcvm.2025.1543153","DOIUrl":"https://doi.org/10.3389/fcvm.2025.1543153","url":null,"abstract":"<p><strong>Background: </strong>Acute heart failure (AHF) is a serious medical condition with considerable morbidity and mortality ranging from 20%-30% within the first month following hospital admission. We aimed to evaluate the efficacy and safety of sodium-glucose cotransporter-2 (SGLT2) inhibitors administered within the first five days of hospitalization for AHF.</p><p><strong>Methods: </strong>We utilized various electronic resources such as MEDLINE, Embase, and the Cochrane Library to retrieve relevant randomized controlled trials (RCTs). The meta-analysis was performed using Revman, where the risk ratio (RR) and mean difference (MD) with a 95% confidence interval (CI) were used for dichotomous and continuous variablesrespectively.</p><p><strong>Results: </strong>A total of seven trials were included in this review. SGLT2 inhibitors were associated with decreased all-cause mortality (RR = 0.61, 95% CI = 0.40, 0.95; <i>P</i> = 0.03), worsening of HF (RR = 0.59, 95%CI = 0.36, 0.97;<i>P</i> = 0.04), and GFR (MD: 1.05, 95% CI = 0.68, 1.43; <i>P</i> < 0.00001) compared with the control group. There were no significant differences between the two groups regarding readmission for HF, cardiovascular mortality, AKI, hypoglycemia, hypotension, and diuretic efficiency. SGLT2 inhibitors were associated with improved KCCQ-CSS scores (MD: -3.82, 95% CI = -7.51, -0.13; <i>P</i> = 0.04).</p><p><strong>Conclusion: </strong>SGLT2 inhibitors demonstrate overall clinical benefits and a favorable safety profile in acute heart failure, although their impact on readmission rates is limited. Further research is needed to refine patient selection and optimize treatment strategies.</p><p><strong>Systematic review registration: </strong>https://www.crd.york.ac.uk/PROSPERO/view/CRD42024571563, PROSPERO (CRD42024571563).</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1543153"},"PeriodicalIF":2.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12078209/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial: Case reports in thrombosis: 2024.","authors":"Luca Spiezia","doi":"10.3389/fcvm.2025.1614440","DOIUrl":"https://doi.org/10.3389/fcvm.2025.1614440","url":null,"abstract":"","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1614440"},"PeriodicalIF":2.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12078201/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of deubiquitinases in cardiovascular diseases: mechanisms and therapeutic implications.","authors":"Xiangyu Fei, Chao Song, Jian Cui, Yuqing Li, Xiaoyong Lei, Huifang Tang","doi":"10.3389/fcvm.2025.1582049","DOIUrl":"https://doi.org/10.3389/fcvm.2025.1582049","url":null,"abstract":"<p><p>Cardiovascular diseases (CVDs) have become the leading cause of death globally, surpassing infectious diseases and other chronic illnesses. The incidence and mortality rates of CVDs are rising worldwide, posing a key challenge in public health. The ubiquitination system is a vast and complex. It is an important post-translational modification that plays a crucial role in various cellular processes. Deubiquitination is catalyzed by deubiquitinases (DUBs), which remove ubiquitin (Ub) from ubiquitinated proteins, thereby reversing the ubiquitination process. DUBs play an important role in many biological processes, such as DNA repair, cell metabolism, differentiation, epigenetic regulation, and protein stability control. They also participate in the regulation of many signaling pathways associated with the development and progression of CVDs. In this review, we primarily focus on the role of DUBs in various key pathological mechanisms of atherosclerosis (AS), such as foam cell formation, vascular remodeling (VR), endothelial-to-mesenchymal transition (End-MT), and clonal hematopoiesis (CH). In the heart, we summarize the involvement of DUBs in diseases and pathological processes, including heart failure (HF), myocardial infarction (MI), myocardial hypertrophy (MH) and ischemia/reperfusion (I/R) injury. Additionally, we also explore the diabetic cardiomyopathy (DCM) and the use of doxorubicin-induced cardiotoxicity in clinical settings. A comprehensive understanding of deubiquitination may provide new insights for the treatment and drug design of CVDs.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1582049"},"PeriodicalIF":2.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12078317/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144077024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Drug-induced cardiac arrest: a pharmacovigilance study from 2004-2024 based on FAERS database.","authors":"Gaocan Ren, Pingping Huang, Jinhui Zhang, Jin Liu, Zian Yan, Xiaochang Ma","doi":"10.3389/fcvm.2025.1498700","DOIUrl":"https://doi.org/10.3389/fcvm.2025.1498700","url":null,"abstract":"<p><strong>Objective: </strong>Utilizing the FDA Adverse Event Reporting System (FAERS) database, this study conducts signal detection for drugs associated with cardiac arrest (CA), aiming to optimize clinical decision-making and ensure safer drug usage.</p><p><strong>Methods: </strong>Adverse event reports related to CA from the first quarter of 2004 to the second quarter of 2024 were extracted from the FAERS database. Signal detection was conducted using the reporting odds ratio (ROR) and proportional reporting ratio (PRR) to identify drugs associated with an increased risk of CA.</p><p><strong>Results: </strong>A total of 66,431 reports were analyzed, comprising 34,508 males (51.9%) and 31,923 females (48.1%). The majority of cases (71.8%) were reported by healthcare professionals, with adults (≥18 years old) representing the predominant group. Clinical outcomes showed that 67.2% of cases resulted in death. Out of 82 drugs with over 100 CA-related reports, 43 displayed positive signals. The top five drugs identified by ROR were: carisoprodol [ROR (95% CI): 34.13 (29.62-39.32)], sugammadex [ROR (95% CI): 26.93 (22.56-32.16)], regadenoson [ROR (95% CI): 20.00 (17.69-22.60)], alprazolam [ROR (95% CI): 12.82 (12.19-13.48)], and propofol [ROR (95% CI): 11.93 (10.61-13.41)]. In the system drug signal detection, musculo-skeletal system drugs ranked highest [ROR (95% CI): 30.99 (27.74-34.62)], followed by alimentary tract and metabolism drugs [ROR (95% CI): 4.75 (4.59-4.92)], nervous system drugs [ROR (95% CI): 4.51 (4.4-4.61)], anti-infective drugs [ROR (95% CI): 4.13 (3.74-4.57)], cardiovascular drugs [ROR (95% CI): 3.89 (3.78-4.01)], and antineoplastic and immunomodulating agents [ROR (95% CI): 2.16 (2.13-2.2)].</p><p><strong>Conclusion: </strong>This study identifies over 40 drugs potentially associated with an elevated risk of CA based on FAERS data. Healthcare professionals should be particularly vigilant when prescribing these drugs, especially to patients with a history of heart disease, and ensure rigorous monitoring of their cardiac health.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1498700"},"PeriodicalIF":2.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12078221/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Commentary: Case Report: Massive intrapericardial hematoma following acupuncture therapy.","authors":"Sun-Jung Lee, Sung-A Kim, Tae-Hun Kim, Jung Won Kang","doi":"10.3389/fcvm.2025.1550391","DOIUrl":"https://doi.org/10.3389/fcvm.2025.1550391","url":null,"abstract":"","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1550391"},"PeriodicalIF":2.8,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12075213/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Qu-shi-hua-tan decoction's efficacy and safety for patients with angina following coronary revascularization: a randomized, double-blind, placebo-controlled trial study protocol.","authors":"Wenjing Xu, Jingwei Wen, Xijiu Li, Xiaoqing Li, Yan Zhang, Weihui Lu","doi":"10.3389/fcvm.2025.1512385","DOIUrl":"https://doi.org/10.3389/fcvm.2025.1512385","url":null,"abstract":"<p><strong>Introduction: </strong>The Qu-shi-hua-tan decoction (QSHTD), formulated by academician Chen Keji, is an empirical decoction for coronary heart disease (CHD). We conducted a randomized controlled trial to assess the effectiveness and safety of QSHTD in managing angina after coronary revascularization (AACR) in CHD patients.</p><p><strong>Methods and design: </strong>This double-blind randomized controlled trial will be conducted at Guangdong Provincial Hospital of Traditional Chinese Medicine. We will allocate 98 qualified participants to either the experimental or control group in a 1:1 ratio through random selection. The experimental group will be given standard care along with QSHTD, whereas the control group will receive standard care and a placebo. The study will span 26 weeks, consisting of a 2-week initial phase, a 12-week intervention phase, and a 12-week monitoring phase. The main outcome measure will be myocardial blood flow (MBF) assessed using adenosine stress real-time myocardial perfusion echocardiography (RTMPE). The secondary outcomes will be Canadian Cardiovascular Sociation Classification, Seattle Angina Questionnaire, Traditional Chinese Medicine (TCM) symptom evaluation; and major adverse cardiac events (MACE).</p><p><strong>Discussion: </strong>This study seeks to deliver compelling proof of the superior methodological and reporting standards of QSHTD's effectiveness and safety within AACR treatment.</p><p><strong>Clinical trial registration: </strong>Chinese Clinical Trial Registration Center [www.chictr.org.cn]. The trial was registered on November 26, 2020 [ChiCTR2000040270].</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1512385"},"PeriodicalIF":2.8,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12075204/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144077000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sudden cardiac death in congenital heart disease-a narrative review and update.","authors":"Frank Han","doi":"10.3389/fcvm.2025.1539958","DOIUrl":"https://doi.org/10.3389/fcvm.2025.1539958","url":null,"abstract":"<p><p>The spectrum of congenital heart disease is extremely varied, from simple septal defects all the way up to complex heterotaxy with multiple overlapping congenitally malformed regions of the heart. While surgical repair has come a long way since the first congenital cardiac surgery, a B-T-T shunt, an unmet need remains as the population continues to experience sudden cardiac arrest at a greater rate than the general population. Many advances in pacing and cardioversion have occurred to address bradyarrhythmias and tachyarrhythmias, but these carry their own adverse effect profile and limitations. This review aims to survey the field, summarize advances, and provide suggestions for future research directions.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1539958"},"PeriodicalIF":2.8,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12076523/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144077012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}